Jaguar Health, Inc.
28.7.2021 14:31:39 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, and member of the board of directors of Napo EU S.p.A., will be aired during an investor webcast tomorrow (Thursday, July 29, 2021) at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A., recently announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros. The registration link for the webcast appears below.
Participation Instructions for Webcast
When: Thursday, July 29, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place July 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657270/REMINDER-FROM-JAGUAR-HEALTH-Innovators-with-Jane-King-Interview-with-Lisa-Conte-to-Air-During-Jaguar-Investor-Webcast-on-Thursday-July-29-2021-at-830-AM-Eastern-to-Provide-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management16.6.2026 23:10:00 CEST | Press release
Milestone reflects Air T's permanent-capital, buy-to-build model and the momentum of its networked aviation portfolio MINNEAPOLIS, MN / ACCESS Newswire / June 16, 2026 / Air T, Inc. (NASDAQ:AIRT) today announced that its majority owned business Crestone Air Partners, a global aviation asset management platform, has completed its acquisition of Arena Aviation Capital - a well-established aviation asset manager with a diversified portfolio and deep airline relationships. The transaction, first disclosed on March 8, 2026, has now closed following the satisfaction of all customary closing conditions and required approvals. The acquisition materially expands Crestone. Assets under management (AUM) as of December 31, 2025, were $800 million; as of March 31, 2026, AUM had grown to $1.2 billion; and post-transaction, the combined platform now comprises $3.6 billion of AUM. Crestone receives standard aviation industry management fees, including origination fees, administrative fees, disposition
On Sale Now! LiberNovo Maxis Big & Tall Ergonomic Chair Debuts, Unlocking a New Level of "Stability, Width, and Comfort" for Prolonged Sitting16.6.2026 18:00:00 CEST | Press release
The Maxis series is live today across the US, Canada, and Europe, starting at €829, with launch savings up to 48% off MSRP. HONG KONG, HK / ACCESS Newswire / June 16, 2026 / LiberNovo's Maxis series goes on sale today, the brand's first line built from the ground up for Big & Tall users rather than scaled up from a standard chair. It ships in three configurations, alongside two additions to the LiberNovo Omni family. Built for the body, not scaled up to fit Maxis targets the three things that fail a larger body in a standard seat: thighs left unsupported, a recline that sways under weight, and support that gives out by mid-afternoon. The 52 cm seat extends fully under the thigh. Multi-density foam holds its shape instead of bottoming out under load. A tall backrest and adjustable neck support hold the spine and neck, with the neck support sitting at the neck rather than behind the head. The frame is BIFMA-certified to 181 kg (399 lb) on a die-cast aluminum alloy base. Recline that hold
MicroVision Brought Onboard by Lake Fusion Technologies and Timberline Aerospace to Accelerate IRIS Sensor Package Deployment16.6.2026 15:20:00 CEST | Press release
Collaboration supports global deployment of advanced situational awareness solutions across commercial, critical infrastructure, security, and government applications REDMOND, WA / ACCESS Newswire / June 16, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, automotive, security and defense applications, today announced recent shipments of its IRIS lidar sensors to Lake Fusion Technologies (LFT) LLC, as LFT and Timberline Aerospace welcome MicroVision onboard to further expand their collaboration and accelerate the deployment of advanced situational awareness solutions. MicroVision recently shipped IRIS sensors to LFT, marking an important milestone as LFT, together with Timberline Aerospace, brings MicroVision more fully into its ecosystem to broaden capabilities and expedite the development and delivery of integrated IRIS Sensor Packages. The deployment will support LFT's continued development and validation activities as it advances sol
Karbon-X Advances Large-Scale Senegal Blue Carbon Project as Second Globally Registered Under Verra's VM0033 Methodology16.6.2026 15:15:00 CEST | Press release
7,500-hectare Senegal blue carbon initiative achieves Verra registration, marking a significant project development milestone for Karbon-X CALGARY, AB / ACCESS Newswire / June 16, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that its Senegal Blue Carbon Mangrove Project has achieved registration under Verra's Verified Carbon Standard (VCS) and Climate, Community & Biodiversity (CCB) Standards, becoming the second project globally to achieve registration under Verra's VM0033 methodology for tidal wetland and seagrass restoration. Located within Senegal's Sine Saloum Delta and Casamance Estuary regions, the approximately 7,500-hectare project is focused on restoring degraded mangrove ecosystems through reforestation and ecosystem recovery activities. Mangrove forests are among the world's most carbon-rich natural environments, capable o
Leggett Dynamics Launches Smart Brushless Motor & Advances Quiet, Software-Defined Comfort & Motion16.6.2026 13:00:00 CEST | Press release
Reduces Complexity & Cost, Improves Performance, Supports Next-Gen Architectures DETROIT, MI / ACCESS Newswire / June 16, 2026 / Leggett Dynamics today launched its Smart Brushless Motor, a next-generation motion system that simplifies design and vehicle integration, improves NVH and durability and supports evolving software architectures across seating and other motion-control applications. Less Complexity, More Capability Unlike conventional systems, Leggett Dynamics' Smart Brushless Motor can operate with or without a seat-level electronic control unit (ECU), enabling direct communication from the vehicle-level ECU to individual actuators. This streamlined approach supports the industry shift toward more centralized or zonal architectures and enables simplified, scalable integration across multiple seat configurations and trim levels with varying actuator counts. In addition, the motor's design reduces packaging size, weight, and wiring complexity while enhancing sound, durability,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom